Enzyme. The enzyme is [**]. The Partner Territory consists of the 27 members of the European Union as of the date of this Agreement, specifically Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK, and Croatia, Albania, Armenia, Azerbaijan, Belarus, Bosnia & ▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ & Montenegro, Tajikistan, Uzbekistan, Turkey, Iceland, Switzerland and Norway. [**] [**] [**] BioSpecifics Technologies Corp. ▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Lynbrook, New York 11563 Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇, President Dear ▇▇▇: In connection with the Amended and Restated Development and License Agreement (the “ License Agreement”) between us, dated as of December , 2008, we wish to confirm to you as follows:
Appears in 2 contracts
Sources: Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc), Development, Commercialization and Supply Agreement (Auxilium Pharmaceuticals Inc)
Enzyme. The enzyme is [***]. The Partner Territory consists of the 27 members of the European Union as of the date of this Agreement, specifically Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK, and Croatia, Albania, Armenia, Azerbaijan, Belarus, Bosnia & ▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ & Montenegro, Tajikistan, Uzbekistan, Turkey, Iceland, Switzerland and Norway. [**] [**] [**] BioSpecifics Technologies Corp. ▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Lynbrook, New York 11563 Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇, President Dear ▇▇▇: In connection with the Amended and Restated Development and License Agreement (the “ " License Agreement”") between us, dated as of December __, 2008, we wish to confirm to you as follows:
Appears in 1 contract
Sources: Development and License Agreement (Biospecifics Technologies Corp)
Enzyme. The enzyme is [**]. The Partner Territory consists of the 27 members of the European Union as of the date of this Agreement, specifically Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK, and Croatia, Albania, Armenia, Azerbaijan, Belarus, Bosnia & ▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ & Montenegro, Tajikistan, Uzbekistan, Turkey, Iceland, Switzerland and Norway. [**] [**] [**] BioSpecifics Technologies Corp. ▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Lynbrook, New York 11563 Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇, President Dear ▇▇▇: In connection with the Amended and Restated Development and License Agreement (the “ License Agreement”) between us, dated as of December __, 2008, we wish to confirm to you as follows:
Appears in 1 contract
Sources: Development and License Agreement (Auxilium Pharmaceuticals Inc)